Uniqure N.V. quarterly report, Q3 FY2021

Business context and reporting period

uniQure N.V. is a gene-therapy developer. This unaudited Form 10-Q covers the quarter and nine months ended September 30, 2021. The results are reported under U.S. GAAP in U.S. dollars. The company’s lead hemophilia B candidate, etranacogene dezaparvovec, was licensed globally to CSL Behring; its other highlighted clinical program is AMT-130 for Huntington’s disease.

Key financial metrics

Nine-month revenue included $462.4 million of CSL Behring license revenue recognized at closing in May; it comprised a $450.0 million upfront payment and $12.4 million related to additional covenants. The company recorded $23.2 million of related contract costs. Q3 revenue was primarily collaboration revenue, including services for CSL Behring and BMS. The nine-month profit and positive operating cash flow therefore substantially reflect a large, non-recurring license transaction, rather than recurring product sales.

At September 30, cash and cash equivalents were $578.5 million, or $581.3 million including restricted cash, versus $244.9 million of cash and cash equivalents at December 31, 2020. Total assets were $774.6 million and total liabilities $183.9 million. Long-term debt was $71.5 million on the balance sheet; outstanding principal under the Hercules facilities was $70.0 million. The facilities mature in June 2023, subject to extension options, and carry restrictive covenants. The company reported compliance with covenants.

Investing cash use was $63.8 million, including $49.9 million net cash for Corlieve and capital spending on facilities. Financing cash provided $65.0 million, including $34.6 million net loan proceeds and $29.6 million net ATM offering proceeds. The filing does not provide quarterly cash-flow figures or a reported gross margin.

Material changes versus the prior comparable period

• Nine-month revenue rose to $466.3 million from $3.4 million, and the company reported $321.4 million net income versus a $124.3 million net loss, principally because of the CSL Behring license revenue.
• Q3 net loss narrowed to $36.5 million from $53.8 million, despite slightly higher operating expenses. A $19.1 million year-over-year swing in quarterly foreign-currency results contributed materially to the improvement.
• Nine-month R&D expense increased $10.5 million and SG&A increased $11.0 million. The filing attributes cost growth in part to hiring, increased disposables and facility expansion; hemophilia B direct R&D spending decreased after CSL Behring assumed development responsibility.
• Cash and cash equivalents increased by $333.5 million from year-end. Debt principal rose from $35.0 million to $70.0 million following the Hercules facility amendment and drawdown.

Outlook, management commentary, risks and unusual items

• Management estimated that September 30 cash would fund operations into the first half of 2024, assuming full repayment of Hercules borrowings by 2023. Achieving $0.3 billion in CSL Behring regulatory, first-commercial-sale and development milestones could extend runway by 12 to 18 months; these payments are contingent, not assured.
• The company expected to submit a U.S. BLA and European MAA for etranacogene dezaparvovec in the first half of 2022, after all 54 HOPE-B participants completed 78-week follow-up. Reported 52-week trial results included mean FIX activity of 41.5% of normal and an 80% reduction in treated annualized bleeding rate from baseline. These are clinical results, not evidence of regulatory approval.
• The FDA removed the hemophilia B program’s clinical hold in April 2021 after a review of a patient’s hepatocellular carcinoma; the company said its investigation found a causal link to treatment highly unlikely. Regulatory, safety and long-term durability risks remain.
• For AMT-130, the first U.S. dose cohort was enrolled and dosing had begun in a higher-dose cohort. The company planned a European Phase I/II study, with enrollment expected before year-end 2021. Trial timing and outcomes remain uncertain.
• Corlieve was acquired on July 30 for AMT-260, a temporal-lobe-epilepsy program. The company recorded provisional IPR&D of $63.3 million, goodwill of $28.2 million and contingent consideration of $23.8 million. Up to $212.4 million of milestone payments may be payable; the valuation is judgment-dependent and the purchase-price allocation was not final. Management noted that final valuation could change the accounting conclusion, potentially requiring asset-acquisition accounting and an expense of the IPR&D asset.
• Other notable items included $21.6 million of nine-month foreign-currency gains, $3.0 million of VectorY-related other income, and $2.6 million of employee-retention credits. A $3.6 million nine-month income-tax expense included a discrete tax adjustment associated with the CSL transaction; the company retained a full valuation allowance on remaining Dutch deferred tax assets.
• Risks include clinical and regulatory uncertainty, manufacturing scale-up and validation, potential COVID-related supply or trial disruption, reliance on collaborators and licensors, financing and debt obligations, and intellectual-property challenges. Pfizer petitioned for inter partes review of two patents relating to FIX Padua; uniQure opposed institution and awaited a decision. Management reported effective disclosure controls and no new material legal proceedings in the period.

Important facts for investors to verify

1. How the CSL Behring transaction’s one-time revenue and cash receipt affect comparisons with future periods, and what milestone, royalty and manufacturing-service revenue is actually earned.
2. Whether the planned first-half 2022 BLA and MAA submissions occurred, and the status of regulatory review, manufacturing validation and long-term HOPE-B safety and efficacy data.
3. AMT-130 trial enrollment, safety findings and development timelines, as well as progress and impairment assumptions for acquired AMT-260.
4. The final Corlieve purchase-price allocation, milestone probabilities and potential cash obligations, including the required purchase of remaining shares.
5. Cash burn excluding the CSL upfront transaction, forecast runway, debt repayment and covenant compliance, and the effects of foreign-exchange movements.
6. The outcome of the patent review petitions and any other changes in intellectual-property, clinical, manufacturing or COVID-related risks.